SITE014-0118

SITE014 (NLD) › SITE014-0118

SITE014-0118

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2026-01-16

completed

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 131); relationship: not assessed

moderate assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 130); relationship: not assessed

mild assessed

Grade 1 Dyspnoea — outcome: UNKNOWN; onset 2022-10-16 (study day 82); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 29); relationship: not assessed

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 27); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.